WO2004087657A1 - 抗肥満剤 - Google Patents
抗肥満剤 Download PDFInfo
- Publication number
- WO2004087657A1 WO2004087657A1 PCT/JP2004/004310 JP2004004310W WO2004087657A1 WO 2004087657 A1 WO2004087657 A1 WO 2004087657A1 JP 2004004310 W JP2004004310 W JP 2004004310W WO 2004087657 A1 WO2004087657 A1 WO 2004087657A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyproline
- food
- feed
- drink
- acyl derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to an anti-obesity agent, and a food and drink, an additive for food and drink, a feed and a feed additive for anti-obesity.
- anti-obesity agents those that suppress the feeding center, such as mazindol (Mazindol 1), and the central nervous system, such as sibutramine (Si butramine), have increased satiety and appetite. Inhibitors and those that suppress the absorption of fat in the stomach and small intestine, such as orris (0r1 istat), are known. However, since there are few drugs that can be used for a long period of time, it is hoped that the demand for anti-obesity drugs will increase in the future and that the choice of anti-obesity drugs will increase.
- Hydroxyproline is widely found in nature as the main constituent amino acid in collagen, and its N-acetyl body is used as an anti-inflammatory agent.
- carbapenum-based antibacterials, antihypertensives, antiasthmatics, and peripheral circulation improvers It is used as a raw material for the synthesis of various pharmaceuticals such as anticoagulants and is also used in cosmetics due to its functional property of having moisturizing properties (Bioscience and Industry, 1998, Vol. 56, No. No. 1, p. 11-16). It is also used as a food additive for adjusting the taste and improving the flavor of fruit juice drinks, soft drinks, and general foods, and as a raw material for flavors. Hirokawa Shoten, 1998, p.D- 1 1 14-1 1 15) G
- Hydroxyproline has pharmacological effects, such as inhibiting skin aging and improving skin quality (WO 00/51561 pamphlet, Japanese Patent Publication No. 2002-80321), anti-inflammatory, anti-rheumatic, analgesic, and wound healing effects (Japanese Patent Publication No. 8-337526). There are no reports on anti-obesity effects. Disclosure of the invention
- An object of the present invention is to provide an anti-obesity agent, or an anti-obesity food or drink, a food or drink additive, a feed or a feed additive.
- the present invention relates to the following (1) to (7).
- An anti-obesity agent containing hydroxyproline or an N-acyl derivative of hydroxyproline or a pharmaceutically acceptable salt thereof as an active ingredient is an anti-obesity agent containing hydroxyproline or an N-acyl derivative of hydroxyproline or a pharmaceutically acceptable salt thereof as an active ingredient.
- An anti-obesity feed or feed additive comprising hydroxyproline or an N-acyl derivative of hydroxyproline or a pharmaceutically acceptable salt thereof as an active ingredient.
- a method for suppressing obesity which comprises administering hydroxyproline or an N-acyl derivative of hydroxyproline or a pharmaceutically acceptable salt thereof.
- hydroxyproline exists widely in nature as a major constituent amino acid component in collagen and as a constituent amino acid of elastin.
- proline is classified into eight different stereoisomers, depending on whether it is in the D-form or the L-form, the position of the hydroxyl group is in the 3- or 4-position, and whether the stereoisomer is in the cis or trans form. It has been known.
- cis-1-hydroxy-1-L-proline cis-4-hydroxy-1-D-proline, cis-3-hydroxy-1-L-proline, cis-3-hydroxy-1-D-proline, trans-1-hydroxy
- Examples include l-L-proline, trans-14-hydroxy-1D-proline, trans-13-hydroxy-1L-proline, and trans-3-hydroxy-1D-proline.
- any hydroxyproline can be used, but trans-4-hydroxy-1L-proline is preferably used.
- Hydroxyproline can be obtained by acid-hydrolyzing collagen derived from animals such as bush and seaweed and purifying it by a conventional method, but hydroxyproline produced using a microorganism is preferably used.
- Microorganisms include Amycolatopsis (genus Amvcolatopsis, Dactvlosporangium) and strains; It is possible to use microorganisms into which the 4-position hydroxylase gene has been introduced. Wear.
- the introduction of a proline 3-hydroxylase or proline 4-hydroxylase gene from a microorganism belonging to a genus selected from the genus Amycolatopsis, Dactylosporandium and Streptomyces into a microorganism is performed by Molecular Cloning, A
- trans-4-hydroxy-1-L-proline is a proline 4-position hydroxylase isolated from a microorganism belonging to the genus Amycolatopsis or Dactylosporandim (Japanese Patent Application Laid-Open No. Hei 7-313179).
- Cis-3-hydroxy-1-L-proline is a proline 3-hydroxylase isolated from a microorganism belonging to the genus Streptomyces (Japanese Patent Application Laid-Open No. 7-322288). No. 5) [Bioindustry, H 31 (1997)].
- N-acyl derivative of hydroxyproline used in the present invention examples include N-acyl derivatives of the above-mentioned various stereoisomers of hydroxyproline.
- the acyl of the N-acyl derivative is not particularly limited, but is preferably an acyl having 2 to 23 carbon atoms, more preferably an acyl having 2 to 12 carbon atoms, and particularly preferably an acyl having 2 to 6 carbon atoms. Specific examples thereof include acetyl, propionyl, butyryl, isoptyryl, valeryl, hexanoyl, heptanoyl, octanoyl, decanoyl, eicosanoyl, tricosanoyl and the like.
- the N-acyl derivative of hydroxyproline can be produced from hydroxyproline by a known method described in, for example, WO 00/51561 pamphlet.
- the obtained N-acyl derivative of hydroxyproline can be purified using a conventional purification method such as crystallization or chromatography.
- Salts of pharmacologically acceptable salts of hydroxyproline or N-acyl derivative of hydroxyproline include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, ammonium and the like. Examples thereof include ammonium salts such as tetramethylammonium, and organic amine addition salts to which morpholine and piperidine are added.
- the antiobesity agent of the present invention is a preparation containing hydroxyproline or an N-acyl derivative of hydroxyproline or a salt thereof as an active ingredient, alone or as a mixture, or as a mixture with any other active ingredient for treatment. is there.
- the preparation is produced by mixing the active ingredient with one or more pharmacologically acceptable carriers and by any method well known in the technical field of pharmaceutics.
- the dosage form of the preparation is preferably the one that is most effective in the treatment, and may be oral administration or parenteral administration such as intravenous, intraperitoneal or subcutaneous administration, but oral administration is preferred.
- parenteral administration such as intravenous, intraperitoneal or subcutaneous administration, but oral administration is preferred.
- Dosage forms include, for example, tablets, powders, granules, pills, suspensions, emulsions, infusions-decoctions, capsules, syrups, solutions, elixirs, extracts, tinctures, liquid extracts It may be any of oral preparations such as preparations, parenteral preparations such as injections, drops, creams, suppositories, etc., but is preferably used as oral preparations.
- additives such as excipients, binders, disintegrants, lubricants, dispersants, suspensions, emulsifiers, diluents, buffers, antioxidants, and bacteria inhibitors are used. Can be used.
- Liquid preparations suitable for oral administration include water, sugars such as sucrose, sorbitol, fructose, glycols such as polyethylene glycol, propylene glycol, sesame oil, oil soybean oil, soybean oil, etc.
- Oils, p-hydroxybenzoic acid Formulated by adding preservatives such as esters, paraoxybenzoic acid derivatives such as methyl parabenzoate, preservatives such as sodium benzoate, flavors such as berry flavor and peppermint, etc. can do.
- Tablets, powders, granules and the like suitable for oral administration include sugars such as lactose, sucrose, pudose, sucrose, mannitol, sorbitol, starch such as potato, wheat, corn, calcium carbonate, calcium sulfate, and carbonate.
- sugars such as lactose, sucrose, pudose, sucrose, mannitol, sorbitol, starch such as potato, wheat, corn, calcium carbonate, calcium sulfate, and carbonate.
- Inorganic substances such as sodium hydrogen, sodium salt, etc., excipients such as crystalline cellulose, plant powders such as corn powder, gentian powder, etc., starch, agar, gelatin powder, crystalline cellulose, carmelo sodium, carmelo calcium, carbonate Disintegrators such as calcium, sodium bicarbonate, sodium alginate, lubricants such as magnesium stearate, talc, hydrogenated vegetable oil, macrogol, silicone oil, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, Etil cellulo Can be formulated by adding Carmelo over scan, gelatin, binding agents of the starch glue solution and the like, surfactants such as fatty acid esters, a plasticizer such as glycerin.
- excipients such as crystalline cellulose, plant powders such as corn powder, gentian powder, etc., starch, agar, gelatin powder, crystalline cellulose, carmelo sodium, carmelo calcium, carbonate Disintegrators such as calcium, sodium bicarbon
- Suitable for parenteral administration comprise a sterile aqueous preparation containing hydroxyproline or an N-acyl derivative of hydroxyproline or a salt thereof, which is preferably isotonic with the blood of the recipient.
- a solution for injection is prepared using a carrier composed of a salt solution, a glucose solution, or a mixture of a salt solution and a putu sugar solution.
- parenteral preparations one selected from the diluents, preservatives, flavors, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc. exemplified for the oral preparations Or more auxiliary components can be added.
- the dosage and frequency of administration of the preparation of the present invention will vary depending on the dosage form, the age and weight of the patient, the nature or severity of the condition to be treated, but usually, the daily dose of hydro ' It is administered once or several times a day so that the N-acyl derivative of xylproline or hydroxyproline or a salt thereof is 5 mg to 500 Omg, preferably 50 mg to 500 Omg.
- the administration period is not particularly limited, but is usually 1 day to 1 year, preferably 2 weeks to 3 months.
- the preparation of the present invention can be used not only for humans but also for animals other than humans (hereinafter abbreviated as non-human animals).
- Non-human animals include non-human animals such as mammals, birds, reptiles, amphibians, and fish.
- the dosage for administration to non-human animals will vary depending on the age, type, and nature or severity of the condition of the animal, but will usually be per lkgl body weight per day of hydroxyproline or an N-acyl derivative of hydroxyproline or
- the salt is administered once to several times a day so as to have a concentration of 0.5 mg to 50 Omg, preferably 5 mg to 500 mg.
- the administration period is not particularly limited, but is usually 1 day to 1 year, preferably 2 weeks to 3 months.
- a carohydrate supplement to food and drink containing hydroxyproline or N-acyl derivative of hydroxypropyl or a salt thereof as an active ingredient can be prepared.
- the food and drink additive of the present invention is processed or manufactured by mixing or dissolving other food and drink additives as necessary, and for example, into the form of powder, granules, pellets, tablets, and various liquid preparations.
- the food and drink of the present invention uses a general method for producing food and drink, except that hydroxyproline or an N-acyl derivative of hydroxyproline or a salt thereof, or the food or drink additive of the present invention is added to the food or drink. Processing and manufacturing it can.
- the food and drink of the present invention include, for example, fluidized bed granulation, stirring granulation, extrusion granulation, tumbling granulation, airflow granulation, compression molding granulation, crushing granulation, spray granulation, spray granulation, etc.
- Granulation method coating method such as pan coating, fluidized bed coating, and dry coating, puff drying, excess steam method, foam matting method, expansion method such as microwave heating method, extrusion granulator, extruder, etc. It can also be manufactured using an extrusion method or the like.
- Examples of the food and drink of the present invention include dairy products such as juices, soft drinks, teas, lactic acid bacteria drinks, fermented milk, frozen desserts, butter, cheese, yogurt, processed milk, skim milk, ham, and sage.
- dairy products such as juices, soft drinks, teas, lactic acid bacteria drinks, fermented milk, frozen desserts, butter, cheese, yogurt, processed milk, skim milk, ham, and sage.
- Meat products such as hamburgers, hamburgers, bamboo rings, fish kneading products such as fried fish, egg rolls, egg products such as egg tofu, cookies, jelly, chewing gum, candy, snacks and other confectionery, breads, and so on.
- Pickles smoked products, dried fish, tsukudani, salted products, spices, seasonings, and the like.
- the food and drink of the present invention may be in the form of, for example, powdered food, sheet food, bottled food, canned food, retort food, capsule food, evening bullet food, liquid food, drink, and the like.
- the food or drink of the present invention can be used as a healthy food or drink having an anti-obesity activity or a functional food or drink.
- the foods and drinks or food and drink additives of the present invention include additives generally used in foods and drinks, for example, those described in the Food Additives Handbook (Japan Food Additives Association, issued on January 6, 1997). Sweeteners, colorants, preservatives, thickeners, antioxidants, color formers, bleaches, fungicides, gum bases, bitters, enzymes, brighteners, acidulants, seasonings, emulsifiers, enhancers, manufacturing Agents, spices, spice extracts and the like may be added.
- Hydroxyproline or N of hydroxyproline in the food or drink of the present invention The amount of the monosyl derivative or salt thereof, or the amount of the food or drink additive is appropriately selected depending on the type of the food or drink, the effect expected from ingestion of the food or drink, and the like. As a derivative or a salt thereof, it is usually 0.1% by weight to 100% by weight, preferably 1.0% by weight to 100% by weight.
- the food or drink of the present invention varies depending on the form of ingestion, the age and weight of the ingestor, etc., but is usually 5 mg to 500 mg of hydroxyproline or an N-acyl derivative of hydroxyproline or a salt thereof per adult day. It is orally administered once or several times a day, that is, ingested so as to be 0 mg, preferably 50 mg to 500 mg.
- the period of ingestion is not particularly limited, but is usually 1 day to 1 year, preferably 2 weeks to 3 months.
- a feed additive containing hydroxyproline or N-acyl derivative of hydroxyproline or a salt thereof as an active ingredient can be prepared in the same manner as the food and drink additive of the present invention.
- the feed additive of the present invention is mixed or dissolved with other feed additives as necessary, and is processed and manufactured into, for example, powders, granules, pellets, tablets, and various liquid forms.
- the feed of the present invention uses a general feed production method except that an N-acyl derivative of hydroxyproline or hydroxyproline or a salt thereof or the feed additive of the present invention is added to a feed for non-human animals. By doing so, it can be processed and manufactured.
- the feed for non-human animals may be any feed for non-human animals such as mammals, birds, reptiles, amphibians, and fish.For example, feed for pets such as dogs, cats, rats, etc. And feed for domestic animals such as bush, feed for poultry such as chicken and turkey, and feed for cultured fish such as Thailand and hamachi.
- Examples of the feed to which the N-acyl derivative of hydroxyproline or hydro, xyproline or its salt or the feed additive of the present invention is added include cereals, rice bran, vegetable oil cake, animal feed raw materials, and other feed raw materials.
- Grains such as refined products include my mouth, wheat, barley, oats, rye, brown rice, buckwheat, millet, millet, fin, corn, soybean, and the like.
- bran examples include rice bran, defatted rice bran, bran, ground powder, wheat germ, wheat bran, pellets, corn bran, corn germ, and the like.
- Vegetable oil cakes include, for example, soybean oil cake, kinako, linseed oil cake, cottonseed oil cake, peanut oil cake, safflower oil cake, palm oil cake, palm oil cake, sesame oil cake, and sunflower oil cake. , Rapeseed oil cake, kapok oil cake, mustard oil cake, etc.
- Animal feed ingredients include, for example, fish meal (north sea meal, imported meal, hole meal, coastal meal), fish soluble, meat meal, meat meal, blood meal, decomposed hair, bone meal, livestock processing by-products, feather meal, Silkworms, skim milk powder, casein, dried whey and the like.
- feed materials include plant foliage (Alf Alpha, Hay Cube, Alpha Alpha Leaf Meal, False Acacia Powder, etc.), corn processing industry by-product (corn gluten meal, corn gluten feed, corn strep plika, etc.), Processed starch (starch, etc.), sugar, fermented industrial products (yeast, beer grounds, malt root, alcohol grounds, soybean grounds, etc.), agricultural production by-products (citrus processed grounds, tofu grounds, coffee grounds, cocoa grounds, etc.), kyassaba , Broad bean, guaryl, seaweed, krill, spirulina, chlorella, and minerals.
- plant foliage Alf Alpha, Hay Cube, Alpha Alpha Leaf Meal, False Acacia Powder, etc.
- corn processing industry by-product corn gluten meal, corn gluten feed, corn strep plika, etc.
- Processed starch starch, etc.
- sugar, fermented industrial products yeast, beer grounds, malt root, alcohol grounds, soybean grounds, etc
- Purified products include proteins (casein, albumin, etc.), amino acids, carbohydrates ( Starch, cellulose, sucrose, glucose, etc.), minerals, bimin, and the like.
- the feed of the present invention includes, for example, fluidized bed granulation, stirring granulation, extrusion granulation, tumbling granulation, gas flow granulation, compression molding granulation, crushing granulation, spray granulation, B granulation, etc.
- Granulation method coating method such as pan coating, fluidized bed coating, dry coating, etc., non-drying, excess steam method, foam matting method, expansion method such as microwave heating method, extrusion by extrusion granulator and extruder etc. It can also be manufactured using a method.
- the feed of the present invention can be used as an anti-obesity feed.
- the amount of hydroxyproline or N-acyl derivative of hydroxyproline or a salt thereof, or a feed additive to be added to the feed of the present invention is appropriately selected according to the type of feed, the effect of the feed, and the effect expected by eating.
- the content of hydroxyproline or an N-acyl derivative of hydroxyproline or a salt thereof is usually 0.1% to 100% by weight, preferably 1.0% to 100% by weight. Is added.
- the feed of the present invention When the feed of the present invention is fed to a non-human animal, it varies depending on the form of intake, the type of animal, the age, body weight, etc. of the animal, but as an N-acyl derivative of hydroxyproline or hydroxyproline or a salt thereof.
- the body weight is 0.5 mg to 50 mg / kg / day, preferably 5 mg to 50 mg / day, orally or several times a day, that is, feed.
- the feeding period is not particularly limited, but is usually 1 day to 1 year, preferably 2 weeks to 3 months. '
- the mice in the first group were fed a commercial feed CE-2 (Clea Japan).
- the mice in the second group were ingested with CE-4 to which 1% by weight of trans-4-hydroxy-1-L-proline (manufactured by Kyowa Hakko Kogyo Co., Ltd .; abbreviated as hydroxyproline) was added.
- mice A third group of mice was ingested with CE-2 supplemented with 1% by weight of trans-N-acetyl-4-hydroxy-L-proline (manufactured by Kyowa Hakko Kogyo Co., Ltd .; hereinafter, abbreviated as N-acetylhydroxyproline). I let you.
- Body weight was measured on the day and 17 days after the start of the test, and food consumption was measured 17 days after the start of the test.
- Table 1 shows the calculation results.
- Water is added to the composition having the composition shown in Table 2 to make 100 ml, and an antiobesity soft drink (for 10 bottles) is produced.
- composition having the composition shown in Table 3 is extracted with 100 ml of water to produce 100 ml of an antiobesity tea beverage.
- Antiobesity tablets (200 mg per tablet) were prepared by the usual method using the formulation shown in Table 6. I do.
- Example 8 An anti-obesity hard capsule (16 O mg per capsule) is produced according to the formulation shown in Table 8. Table 8
- hydroxyproline To 5 Omg of hydroxyproline, 6 Omg of lactose and 30 mg of corn starch are added and mixed, and an aqueous solution of 2 Omg of hydroxypropylcellulose is added and kneaded. Next, granules are produced by an ordinary method using an extrusion granulator. Hard granules are manufactured by filling the granules into gelatin hard capsules.
- Anti-obesity soft capsules (17 Omg per capsule)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002520375A CA2520375A1 (en) | 2003-03-28 | 2004-03-26 | Anti-obesity agent |
US10/549,157 US20060264498A1 (en) | 2003-03-28 | 2004-03-26 | Anti-obesity agent |
EP04723845A EP1612206A4 (en) | 2003-03-28 | 2004-03-26 | ANTI-OBESITY AGENT |
JP2005504207A JPWO2004087657A1 (ja) | 2003-03-28 | 2004-03-26 | 抗肥満剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-089985 | 2003-03-28 | ||
JP2003089985 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087657A1 true WO2004087657A1 (ja) | 2004-10-14 |
Family
ID=33127253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004310 WO2004087657A1 (ja) | 2003-03-28 | 2004-03-26 | 抗肥満剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060264498A1 (ja) |
EP (1) | EP1612206A4 (ja) |
JP (1) | JPWO2004087657A1 (ja) |
KR (1) | KR20050106528A (ja) |
CN (1) | CN100351232C (ja) |
CA (1) | CA2520375A1 (ja) |
WO (1) | WO2004087657A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131836A2 (en) * | 2005-03-22 | 2006-12-14 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
WO2007129725A1 (ja) * | 2006-05-09 | 2007-11-15 | Kyowa Hakko Bio Co., Ltd. | 肝障害抑制剤 |
WO2008146907A1 (ja) * | 2007-06-01 | 2008-12-04 | Kyowa Hakko Bio Co., Ltd. | 経口組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007107008A1 (en) * | 2006-03-22 | 2007-09-27 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity |
AU2012262533A1 (en) * | 2011-05-27 | 2013-12-19 | Allergan, Inc. | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders |
DE102011107854A1 (de) * | 2011-07-01 | 2013-01-03 | Stefanie Alber | Futtermittel |
JP2022549772A (ja) * | 2019-09-23 | 2022-11-29 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 減量の改善及び維持のための組成物及び方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63218621A (ja) * | 1987-03-09 | 1988-09-12 | Kazuoki Tsuchiya | 肥満症の予防・治療用組成物 |
JPH0624977A (ja) * | 1992-07-10 | 1994-02-01 | Rikagaku Kenkyusho | 抗肥満剤及び抗高脂血症剤 |
JPH09104624A (ja) * | 1995-10-09 | 1997-04-22 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖を主体とする組成物、甘味料、食品及び飼料 |
JP2004091475A (ja) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | 高遊離脂肪酸血症の予防または改善用組成物 |
JP2004091476A (ja) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | 高トリグリセライド血症の予防または改善用組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995027408A1 (en) * | 1994-04-11 | 1995-10-19 | East Wellsum Industries(S) Pte. Ltd. | Sweetening agent containing glycine, l-proline and/or l-hydroxyproline |
EP1159952B1 (en) * | 1999-03-02 | 2009-01-14 | Kyowa Hakko Kogyo Co., Ltd. | N-Acetylhydroxyproline for improving the moisture retention function of the epidermis |
WO2002006225A1 (fr) * | 2000-07-19 | 2002-01-24 | Kyowa Hakko Kogyo Co., Ltd. | Agents de prevention ou de traitement de la dermite atopique |
US20040048772A1 (en) * | 2001-01-05 | 2004-03-11 | Ryusuke Nakagiri | Preventives for arthritis |
-
2004
- 2004-03-26 WO PCT/JP2004/004310 patent/WO2004087657A1/ja not_active Application Discontinuation
- 2004-03-26 CN CNB2004800085841A patent/CN100351232C/zh not_active Expired - Fee Related
- 2004-03-26 CA CA002520375A patent/CA2520375A1/en not_active Abandoned
- 2004-03-26 EP EP04723845A patent/EP1612206A4/en not_active Withdrawn
- 2004-03-26 JP JP2005504207A patent/JPWO2004087657A1/ja active Pending
- 2004-03-26 KR KR1020057018323A patent/KR20050106528A/ko not_active Application Discontinuation
- 2004-03-26 US US10/549,157 patent/US20060264498A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63218621A (ja) * | 1987-03-09 | 1988-09-12 | Kazuoki Tsuchiya | 肥満症の予防・治療用組成物 |
JPH0624977A (ja) * | 1992-07-10 | 1994-02-01 | Rikagaku Kenkyusho | 抗肥満剤及び抗高脂血症剤 |
JPH09104624A (ja) * | 1995-10-09 | 1997-04-22 | Hokuren Federation Of Agricult Coop:The | α−グルコシダーゼ阻害剤、それを含む糖を主体とする組成物、甘味料、食品及び飼料 |
JP2004091475A (ja) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | 高遊離脂肪酸血症の予防または改善用組成物 |
JP2004091476A (ja) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | 高トリグリセライド血症の予防または改善用組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1612206A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131836A2 (en) * | 2005-03-22 | 2006-12-14 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
WO2006131836A3 (en) * | 2005-03-22 | 2007-10-04 | Innodia Inc | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
WO2007129725A1 (ja) * | 2006-05-09 | 2007-11-15 | Kyowa Hakko Bio Co., Ltd. | 肝障害抑制剤 |
WO2008146907A1 (ja) * | 2007-06-01 | 2008-12-04 | Kyowa Hakko Bio Co., Ltd. | 経口組成物 |
JP2014210792A (ja) * | 2007-06-01 | 2014-11-13 | 協和発酵バイオ株式会社 | 経口組成物 |
JP5632162B2 (ja) * | 2007-06-01 | 2014-11-26 | 協和発酵バイオ株式会社 | 経口組成物 |
US9492494B2 (en) | 2007-06-01 | 2016-11-15 | Kyowa Hakko Bio Co., Ltd. | Oral composition |
Also Published As
Publication number | Publication date |
---|---|
CA2520375A1 (en) | 2004-10-14 |
KR20050106528A (ko) | 2005-11-09 |
CN1768035A (zh) | 2006-05-03 |
EP1612206A1 (en) | 2006-01-04 |
US20060264498A1 (en) | 2006-11-23 |
CN100351232C (zh) | 2007-11-28 |
EP1612206A4 (en) | 2007-10-10 |
JPWO2004087657A1 (ja) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2156751B1 (en) | Novel sweetener having sugar-like taste and production method and use of the same | |
EP1913943B1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
JPWO2002055074A1 (ja) | 関節炎の予防剤または治療剤 | |
JPWO2006033355A1 (ja) | 皮膚の乾燥予防または改善用経口剤 | |
CA2519250C (en) | Therapeutic agent for diabetes mellitus | |
WO2004087657A1 (ja) | 抗肥満剤 | |
WO2004039368A1 (ja) | アトピー性皮膚炎の予防または治療用経口剤 | |
WO2002055073A1 (fr) | Agents prophylactiques de l'arthrite | |
JP5885784B2 (ja) | 経口組成物 | |
JP2004292325A (ja) | 筋肉増強剤および筋肉減衰の予防または治療剤 | |
JP2004256403A (ja) | TNF−α産生抑制剤 | |
WO2004085389A1 (ja) | 脂質代謝改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504207 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006264498 Country of ref document: US Ref document number: 10549157 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004723845 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520375 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057018323 Country of ref document: KR Ref document number: 20048085841 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057018323 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004723845 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10549157 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004723845 Country of ref document: EP |